simply becomes the safety threshold in the observational monitoring activity.
If stated relative to no treatment, one must then determine
the amount by which the comparator increases
the risk of the outcome relative to no treatment in order
to determine the maximum tolerable RR or RD comparing
the new drug to the active comparator. This concept
is similar to selecting a NI margin in efficacy trials.